Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

for
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-),
Location: New York NY, Long Island City NY, Grand Rapids MI,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07318805

Phase 1, Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: Providence RI, New York NY, Fairfax VA, Durham NC,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase 1, Recruiting

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

for
Adenocarcinoma of the Breast, Breast Cancer,
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 70+

Code: NCT07768436

Phase 2, Recruiting

Intratumoral N17350 in Advanced Solid Tumors

for
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative,
Location: Buffalo NY, Houston TX, San Diego CA, Los Angeles CA
Sponsor: Onchilles Pharma Inc

Sex: All

Age: 18+

Code: NCT07339176

Phase 1, Phase 2, Recruiting

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

for
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Location: Los Angeles CA
Sponsor: Stephen Shiao

Sex: Female

Age: 18+

Code: NCT05491226

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for
Metastatic Solid Tumor, Recurrent Solid Tumor,
Location: Boston MA, New York NY, Cleveland OH, Atlanta GA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06465069

Phase 1, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: St. John's, Westbrook ME, Boston MA, Quebec, Sherbrooke,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06966700

Phase 3, Recruiting

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

for
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05504707

Phase 1, Recruiting

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

for
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer,
Location: Boston MA, Philadelphia PA, Nashville TN,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04434040

Phase 2, Recruiting

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

for
Soft-tissue Sarcoma, Triple Negative Breast Cancer,
Location: Orange CA
Sponsor: University of California, Irvine

Sex: All

Age: 18+

Code: NCT07064018

Phase 1, Phase 2, Recruiting

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

for
Breast Cancer, Triple Negative Breast Cancer
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT06435351

Early Phase 1, Recruiting

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

for
HER2-negative Breast Cancer, Metastatic Breast Cancer,
Location: Bethesda MD, Houston TX
Sponsor: The Methodist Hospital Research Institute

Sex: All

Age: 18+

Code: NCT05660083

Phase 2, Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Location: Brewer ME, South Weymouth MA, Boston MA, Foxborough MA,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04468061

Phase 2, Recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

for
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06318897

Phase 2, Recruiting

Sacituzumab Govitecan In TNBC

for
Invasive Breast Cancer, Triple Negative Breast Cancer,
Location: Danvers MA, Boston MA, Newton MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT04230109

Phase 2, Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary,
Location: Providence RI, New Haven CT, New York NY, Baltimore MD,
Sponsor: Volastra Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05902988

Phase 1, Phase 2, Recruiting

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Scottsdale AZ
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06635980

Phase 2, Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

for
Breast Cancer, Breast Neoplasm, Breast Cancer Female,
Location: Houston TX
Sponsor: Baylor Breast Care Center

Sex: All

Age: 18+

Code: NCT05020860

Phase 2, Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: Hackensack NJ, Montreal, Hamilton, Nashville TN,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase 1, Phase 2, Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for
Non Small Cell Lung Cancer, Esophageal Cancer,
Location: Boston MA, New Haven CT, New York NY,
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT05983432

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial